QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data — Here’s What Investors Need To Know

Shares of uniQure (QURE) crashed more than 50% in pre-market trading on Tuesday after data for its experimental Huntington’s disease gene therapy raised questions about how well its treatment effect holds up over time.The therapy is particularly important because there are currently no approved tre…